SAN FRANCISCO, June 24, 2020 — Quit Genius, the first technology-enabled digital clinic for multiple addictions, launched their solutions for alcohol and opioid addictions today.
In April, in response to the COVID-19 pandemic, the FDA updated the regulatory requirements for treating psychiatric disorders, including substance use disorders. The new guidance facilitates the treatment of substance use disorders through digital health devices, without the need for in-clinic visits.
Adding to Quit Genius’ industry-leading tobacco cessation program (52% quit rates), the company will now offer integrated support for alcohol and opioid addictions to help support patients during the pandemic and beyond. The company has pioneered a new model of physician-led care that combines counseling, medication-assisted treatment (MAT), supervised drug testing, and peer support.
The Quit Genius solution uses technology to deliver the full treatment program remotely within the privacy of a patient’s home. The program will be available to enterprise and health plan customers in the US.
“Quit Genius has delivered industry-leading health outcomes and a meaningful return on investment for our customers thus far. With COVID-19, we have seen a positive acceleration in the adoption of digital health solutions. This expansion makes Quit Genius the first digital therapeutics program for poly-substance addictions and represents a big step in our mission of helping 100 million people conquer their substance addictions.” said Quit Genius CEO, Yusuf Sherwani, MD.
“With 1 in 4 workers battling addiction and one-third of them having more than one addiction, poly-substance addictions are unfortunately common. Delivering holistic care, that treats the ‘whole person’, irrespective of their addiction or combination of addictions has been a core part of our product strategy from day one and will go a long way to enable our members to live addiction-free lives.” said Chief Product Officer, Sarim Siddiqui, MD.
About Pelago
Pelago is the leading specialty substance use care provider for employers and health plans, delivering virtual, evidence-based care for alcohol, tobacco, opioid, and cannabis use. Its integrated care model combines digital tools, live counseling, and medication-assisted treatment, with same-day access available nationwide. Built by leading addiction specialists, Pelago is the only substance use care solution with published, peer-reviewed evidence demonstrating both clinical impact and medical cost savings. Through its outcomes-backed approach, Pelago helps organizations reduce high-cost medical claims while providing a confidential, stigma-free benefit that employees trust. Today, over 4 million people have access to Pelago.
Say hello to brighter days together
Get started quickly. Save costs. Change lives forever.